hengrui glp 1 China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes China's Hengrui Grants Global Rights
Description
Berberine and GLP-1 receptor agonists are distinct compounds with different mechanisms of action
This global initiative reframed obesity as a chronic, systemic disease rather than a mere risk factor
We also observed no changes in motor neuron counts or glial activation in lumbar spinal cords of liraglutide treated mice compared to vehicle dosed mice
If you're not on a GLP-1, there are better-targeted options for general nutritional support
